Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0M5EC
|
|||
| Drug Name |
PMID27336223-Compound-8
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
CORNELL UNIVERSITY
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H26O2
|
|||
| Canonical SMILES |
CCCCCCCCC1=CC=C(C=C1)C2=CC=C(C=C2)C(=O)O
|
|||
| InChI |
1S/C21H26O2/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)19-13-15-20(16-14-19)21(22)23/h9-16H,2-8H2,1H3,(H,22,23)
|
|||
| InChIKey |
HXBKPYIEQLLNBK-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 59662-49-6
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:95048
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Retinoic acid receptor beta (RARB) | Target Info | Agonist | [1] |
| Target's Patent Info | Retinoic acid receptor beta (RARB) | Target's Patent Info | [1] | |
| KEGG Pathway | Pathways in cancer | |||
| Small cell lung cancer | ||||
| Non-small cell lung cancer | ||||
| Reactome | Nuclear Receptor transcription pathway | |||
| WikiPathways | Vitamin A and Carotenoid Metabolism | |||
| Nuclear Receptors in Lipid Metabolism and Toxicity | ||||
| Mesodermal Commitment Pathway | ||||
| Integrated Pancreatic Cancer Pathway | ||||
| Nuclear Receptors | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Therapeutic use of selective synthetic ligands for retinoic acid receptors: a patent review.Expert Opin Ther Pat. 2016 Aug;26(8):957-71. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.